170 related articles for article (PubMed ID: 17391791)
1. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397).
Dearnaley DP; Sydes MR; Langley RE; Graham JD; Huddart RA; Syndikus I; Matthews JH; Scrase CD; Jose CC; Logue J; Stephens RJ;
Radiother Oncol; 2007 Apr; 83(1):31-41. PubMed ID: 17391791
[TBL] [Abstract][Full Text] [Related]
2. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial.
Dearnaley DP; Sydes MR; Graham JD; Aird EG; Bottomley D; Cowan RA; Huddart RA; Jose CC; Matthews JH; Millar J; Moore AR; Morgan RC; Russell JM; Scrase CD; Stephens RJ; Syndikus I; Parmar MK;
Lancet Oncol; 2007 Jun; 8(6):475-87. PubMed ID: 17482880
[TBL] [Abstract][Full Text] [Related]
3. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects.
Dearnaley DP; Hall E; Lawrence D; Huddart RA; Eeles R; Nutting CM; Gadd J; Warrington A; Bidmead M; Horwich A
Br J Cancer; 2005 Feb; 92(3):488-98. PubMed ID: 15685244
[TBL] [Abstract][Full Text] [Related]
4. Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397).
Syndikus I; Morgan RC; Sydes MR; Graham JD; Dearnaley DP;
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):773-83. PubMed ID: 19836155
[TBL] [Abstract][Full Text] [Related]
5. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial.
Dearnaley DP; Jovic G; Syndikus I; Khoo V; Cowan RA; Graham JD; Aird EG; Bottomley D; Huddart RA; Jose CC; Matthews JH; Millar JL; Murphy C; Russell JM; Scrase CD; Parmar MK; Sydes MR
Lancet Oncol; 2014 Apr; 15(4):464-73. PubMed ID: 24581940
[TBL] [Abstract][Full Text] [Related]
6. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406.
Michalski JM; Purdy JA; Winter K; Roach M; Vijayakumar S; Sandler HM; Markoe AM; Ritter MA; Russell KJ; Sailer S; Harms WB; Perez CA; Wilder RB; Hanks GE; Cox JD
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):391-402. PubMed ID: 10661346
[TBL] [Abstract][Full Text] [Related]
7. ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.
Rodda S; Tyldesley S; Morris WJ; Keyes M; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):286-295. PubMed ID: 28433432
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma.
Sanguineti G; Agostinelli S; Foppiano F; Franzone P; Garelli S; Marcenaro M; Orsatti M; Vitale V
Br J Cancer; 2002 Jun; 86(12):1843-7. PubMed ID: 12085173
[TBL] [Abstract][Full Text] [Related]
9. Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial.
Kass-Iliyya A; Jovic G; Murphy C; Fisher C; Syndikus I; Jose C; Scrase CD; Graham JD; Nicol D; Sydes MR; Dearnaley D
Eur Urol; 2018 Jun; 73(6):968-976. PubMed ID: 29307509
[TBL] [Abstract][Full Text] [Related]
10. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
[TBL] [Abstract][Full Text] [Related]
11. Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II.
Michalski JM; Winter K; Purdy JA; Wilder RB; Perez CA; Roach M; Parliament MB; Pollack A; Markoe AM; Harms W; Sandler HM; Cox JD
Int J Radiat Oncol Biol Phys; 2003 May; 56(1):192-8. PubMed ID: 12694838
[TBL] [Abstract][Full Text] [Related]
12. The impact of clinical factors on the development of late radiation toxicity: results from the Medical Research Council RT01 trial (ISRCTN47772397).
Barnett GC; De Meerleer G; Gulliford SL; Sydes MR; Elliott RM; Dearnaley DP
Clin Oncol (R Coll Radiol); 2011 Nov; 23(9):613-24. PubMed ID: 21470834
[TBL] [Abstract][Full Text] [Related]
13. Late rectal and urinary toxicity from conformal, dose-escalated radiation therapy for prostate cancer: a prospective study of 402 patients.
Lin C; Turner S; Mai T; Kneebone A; Gebski V
Australas Radiol; 2007 Dec; 51(6):578-83. PubMed ID: 17958696
[TBL] [Abstract][Full Text] [Related]
14. RTOG 94-06: is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity?
Valicenti RK; Winter K; Cox JD; Sandler HM; Bosch W; Vijayakumar S; Michalski J; Purdy J
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):614-20. PubMed ID: 14529764
[TBL] [Abstract][Full Text] [Related]
15. Dynamic conformal arc radiotherapy with rectum hollow-out technique for localized prostate cancer.
Tomita N; Kodaira T; Tachibana H; Nakamura T; Tomoda T; Nakahara R; Inokuchi H; Hayashi N; Fuwa N
Radiother Oncol; 2009 Mar; 90(3):346-52. PubMed ID: 18950880
[TBL] [Abstract][Full Text] [Related]
16. Androgen ablation therapy does not increase the risk of late morbidity following 3D-conformal radiotherapy of organ-confined prostate cancer: the experience of the European Institute of Oncology.
Greco C; Castiglioni S; Fodor A; Mazzetta C; De Cobelli O; Orecchia R
Tumori; 2004; 90(6):567-72. PubMed ID: 15762358
[TBL] [Abstract][Full Text] [Related]
17. Impact of neoadjuvant androgen ablation and other factors on late toxicity after external beam prostate radiotherapy.
Liu M; Pickles T; Agranovich A; Berthelet E; Duncan G; Keyes M; Kwan W; McKenzie M; Morris J; Pai H; Tyldesley S; Wu J
Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):59-67. PubMed ID: 14697421
[TBL] [Abstract][Full Text] [Related]
18. Gastro-intestinal and genito-urinary morbidity after 3D conformal radiotherapy of prostate cancer: observations of a randomized trial.
Koper PC; Jansen P; van Putten W; van Os M; Wijnmaalen AJ; Lebesque JV; Levendag PC
Radiother Oncol; 2004 Oct; 73(1):1-9. PubMed ID: 15465140
[TBL] [Abstract][Full Text] [Related]
19. Dose/volume relationship of late rectal bleeding after external beam radiotherapy for localized prostate cancer: absolute or relative rectal volume?
Kupelian PA; Reddy CA; Carlson TP; Willoughby TR
Cancer J; 2002; 8(1):62-6. PubMed ID: 11895204
[TBL] [Abstract][Full Text] [Related]
20. Implementing the UK Medical Research Council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer.
Sydes MR; Stephens RJ; Moore AR; Aird EG; Bidmead AM; Fallowfield LJ; Graham J; Griffiths S; Mayles WP; McGuire A; Stanley S; Warrington AP; Dearnaley DP;
Radiother Oncol; 2004 Aug; 72(2):199-211. PubMed ID: 15297138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
